Elabela as a novel marker: Well-correlated with WIfI amputation risk score in lower extremity arterial disease patients
ANATOLIAN JOURNAL OF CARDIOLOGY, cilt.25, sa.5, ss.330-337, 2021 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 25 Sayı: 5
- Basım Tarihi: 2021
- Doi Numarası: 10.14744/anatoljcardiol.2020.17329
- Dergi Adı: ANATOLIAN JOURNAL OF CARDIOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.330-337
- Hacettepe Üniversitesi Adresli: Evet
Özet
Objective: Worldwide, over 200 million people are diagnosed with lower extremity arterial disease (LEAD). LEAD significantly increases the risk of death and amputation of the lower limb. A new classification system (WIfI) has been proposed to initially assess all patients with ischemic rest pain or wounds and also predicts 1-year amputation risk. Elabela is a bioactive peptide and a part of the apelinergic system, which has beneficial effects on body fluid homeostasis and cardiovascular health. We aimed to investigate serum Elabela levels in LEAD.